Research material raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-24 and is reviewed periodically as new material appears.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
=== Anti-inflammatory uses === One of its therapeutic effects is its ability to reduce inflammatory responses by decreasing synthesis of pro-inflammatory cytokines and inhibiting inflammatory signaling pathways, such as NF-kB. Excessive inflammation not only further damages tissue but also slows the healing process, making PDRN's anti-inflammatory activity as a key feature of its effects. PDRN showed modulation of markers connected to chronic low-grade inflammation (also referred to as inflammaging) and age-related deterioration, suggesting these properties may enhance tissue homeostasis under conditions of prologed stress.
==== Indications ==== Dronabinol, also known as tetrahydrocannabinol (THC), is a natural compound extracted from plants. It is available as Marinol® and Syndros®. It is used as an appetite stimulant in anorexia-associated weight loss in HIV/AIDS patients. An increase in patients' appetite and daily calorie intake with minimal improvement in weight and nausea is reported. Dronabinol is also indicated for chemotherapy-induced nausea and vomiting in cancer patients failing to respond to conventional antiemetics. Dronabinol is also used for cancer-related chronic pain in Europe.
=== April === 3 April – Ted Hipkiss, cricketer (Northern Districts) (born 1947). 5 April Raymond Hawthorne, actor (Mortimer's Patch, Bread and Roses, Shortland Street) and theatre director (Mercury Theatre, National Opera of New Zealand) (born 1936). Di McCarthy, behavioural neuroscientist (University of Auckland), chief executive of the Royal Society of New Zealand Te Apārangi (2007–2014). 6 April Sue Berry, physiotherapist and businesswoman, co-founder of Whitestone Cheese (1987) (born 1944). Avis Fletcher, Olympic hurdler and sprinter (1964), British Empire and Commonwealth Games double bronze medallist (1962) (born 1938). 9 April Nancy Carr, home economist (University of Otago) (born 1936). John Mayhew, sports physician (All Blacks, North Harbour, New Zealand Warriors) (born 1954). 11 April – Robyn Kahukiwa, artist, children's writer and illustrator, Te Tohu mō Te Arikinui Dame Te Atairangikaahu (2020) (born 1938). 13 April John Bradshaw, geologist (University of Canterbury), Fellow of the Royal Society of New Zealand (since 1999) (born 1939). David Kernohan, architect and academic (Victoria University of Wellington) (born 1947). 14 April – Peter Matheson, theologian (University of Otago) (born 1938). 16 April – Roger McLachlan, rock bassist (Little River Band) (born 1954). 18 April – Bill Woods, local politician and community leader, Mayor of Selwyn (1992–1995) (born 1942). 19 April – Peter Hilt, politician, MP for Glenfield (1990–1996) (born 1942).
=== Monitor/recorder === The flow cells are connected to a display and/or recorder. On older systems this was a simple chart recorder, on modern systems a computer with hardware interface and display is used. This permits the experimenter to identify when peaks in protein concentration occur, indicating that specific components of the mixture are being eluted.
Sources: en.wikipedia.org
== Functions == Endorphins play a major role in the body's inhibitory response to pain. Research has demonstrated that meditation by trained individuals can be used to trigger endorphin release. Laughter may also stimulate endorphin production and elevate one's pain threshold. Endorphin production can be triggered by vigorous aerobic exercise. The release of β-endorphin has been postulated to contribute to the phenomenon known as "runner's high". However, experimental blockade of the mu opioid receptor has shown that endorphins are not strictly necessary for the development of exercise-induced euphoria. It has been suggested that other neurotransmitters, namely endocannabinoids, are more likely contributors. Endorphins may partially mediate exercise-induced analgesia.
== Interactions == Besides integrin, fibronectin binds to many other host and non-host molecules. For example, it has been shown to interact with proteins such fibrin, tenascin, TNF-α, BMP-1, rotavirus NSP-4, and many fibronectin-binding proteins from bacteria (like FBP-A; FBP-B on the N-terminal domain), as well as the glycosaminoglycan, heparan sulfate. pUR4 is a recombinant peptide that is known to inhibit the polymerization of fibronectin in a number of cell types including fibroblasts and endothelial cells. Fibronectin has been shown to interact with:
Since the release of nonbenzodiazepines, also known as z-drugs, in 1992 in response to safety concerns, individuals with insomnia and other sleep disorders have increasingly been prescribed nonbenzodiazepines (2.3% in 1993 to 13.7% of Americans in 2010), and less often prescribed benzodiazepines (23.5% in 1993 to 10.8% in 2010). It is not clear as to whether the new non benzodiazepine hypnotics (Z-drugs) are better than the short-acting benzodiazepines. The efficacy of these two groups of medications is similar. According to the US Agency for Healthcare Research and Quality, indirect comparison indicates that side-effects from benzodiazepines may be about twice as frequent as from nonbenzodiazepines. Some experts suggest using nonbenzodiazepines preferentially as a first-line long-term treatment of insomnia. However, the UK National Institute for Health and Clinical Excellence did not find any convincing evidence in favor of Z-drugs. NICE review pointed out that short-acting Z-drugs were inappropriately compared in clinical trials with long-acting benzodiazepines. There have been no trials comparing short-acting Z-drugs with appropriate doses of short-acting benzodiazepines. Based on this, NICE recommended choosing the hypnotic based on cost and the patient's preference. Older adults should not use benzodiazepines to treat insomnia unless other treatments have failed.
== Adverse effects == Adverse effects associated with the MMR vaccine include fever, rash, injection site pain, and, in rare cases, red or purple discolorations on the skin known as thrombocytopenic purpura, or seizures related to fever (febrile seizure).
Contrasting with the classic Staudinger reaction, Staudinger ligation is a second order reaction in which the rate-limiting step is the formation of phosphazide (specific reaction mechanism shown in Figure 9). The triphenylphosphine first reacts with the azide to yield an azaylide through a four-membered ring transition state, and then an intramolecular reaction leads to the iminophosphorane intermediate, which will then give the amide-linkage under hydrolysis.
Sources: en.wikipedia.org
The upper town is composed of three parts: the "coast", the suburban districts of the plateau, and large peripheral housing estates. The neighbourhoods on the "coast" (the Dead Cliff) are residential – more prosperous in the western part (Les Ormeaux, Rue Felix Faure) and more modest to the east (St. Cecilia, Aplemont). The Jenner tunnel passes under the "coast" and connects the upper town to the lower town. It is also on the coast that there are two fortifications of the city, Forts Sainte-Adresse and Tourneville, and the main cemetery (Sainte-Marie cemetery). With the demise of the military functions of the city, the forts are gradually being converted: Fort Sainte-Adresse houses the Hanging Gardens and Fort Tourneville hosted the Tetris project in 2013 – an axis of contemporary music with concert halls and rehearsal studios. To the north of the "coast" suburban districts such as Rouelles, Sainte-Cecile, la Mare au Clerc, Sanvic, Bleville, and Dollemard were developed during the first half of the 19th century. In their extension North-west between Bleville and Octeville airport a new area is being developed: "Les Hauts de Bleville". This eco-district made up of housing units to HQE standards, a Joint Development Area (ZAC), and a school should have a total of 1,000 housing units. The peripheral suburbs of the commune grew in the postwar period. These are large housing estates in Caucriauville, Bois de Bleville, Mont-Gaillard, and Mare-rouge where a disadvantaged population is concentrated.
== External links == Histology image: 13906loa – Histology Learning System at Boston University - "Respiratory System: lung (human), alveolar macrophages" Histology at KUMC resp-resp16 "Alveoli" Slide at ufl.edu
Amanita phalloides ( AM-ə-NY-tə fə-LOY-deez), commonly known as the death cap, is a deadly poisonous basidiomycete fungus and mushroom, one of many in the genus Amanita. Originating in Europe but later introduced to other parts of the world since the late twentieth century, A. phalloides forms ectomycorrhizae with various broadleaved trees. In some cases, the death cap has been introduced to new regions with the cultivation of non-native species of oak, chestnut, and pine. The large fruiting bodies appear in summer and autumn; the caps are generally greenish in colour with a white stipe and gills. The cap colour is variable, including white forms, and is thus not a reliable identifier. The death cap resembles several edible species (most notably Caesar's mushroom and the straw mushroom) commonly consumed by humans, increasing the risk of accidental poisoning. Amatoxins, a class of toxins found in mushrooms like A. phalloides, are thermostable: they resist changes due to heat and cold, so their toxic effects are not reduced by cooking or freezing. Amanita phalloides is the most poisonous of all known mushrooms. It is estimated that as little as half a mushroom contains enough toxin to kill an adult human. It is also the deadliest mushroom worldwide, responsible for 90% of mushroom-related fatalities every year. It has been involved in the majority of human deaths from mushroom poisoning, possibly including Roman Emperor Claudius in AD 54 and Holy Roman Emperor Charles VI in 1740.
== Early life == Geneviève Meurgues was born on 4 February 1931 in Paris, into a family originally from Saint-Germain-de-Modéon. She had sister and brother, Christiane and Bernard. Until 1962, she worked in a medical analysis laboratory while completing her education in chemistry and biochemistry at the Conservatoire national des arts et métiers. She graduated as a chemical engineer in 1967, writing her thesis on the nucleic acids of the fungus Aspergillus niger.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.